These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 23032625)

  • 1. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile.
    Hainsworth JD; Schnabel CA; Erlander MG; Haines DW; Greco FA
    Clin Colorectal Cancer; 2012 Jun; 11(2):112-8. PubMed ID: 22000811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.
    Hayashi H; Kurata T; Takiguchi Y; Arai M; Takeda K; Akiyoshi K; Matsumoto K; Onoe T; Mukai H; Matsubara N; Minami H; Toyoda M; Onozawa Y; Ono A; Fujita Y; Sakai K; Koh Y; Takeuchi A; Ohashi Y; Nishio K; Nakagawa K
    J Clin Oncol; 2019 Mar; 37(7):570-579. PubMed ID: 30653423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
    Varadhachary GR; Talantov D; Raber MN; Meng C; Hess KR; Jatkoe T; Lenzi R; Spigel DR; Wang Y; Greco FA; Abbruzzese JL; Hainsworth JD
    J Clin Oncol; 2008 Sep; 26(27):4442-8. PubMed ID: 18802157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-Specific and Targeted Therapy Based on Molecular Profiling by Next-Generation Sequencing for Cancer of Unknown Primary Site: A Nonrandomized Phase 2 Clinical Trial.
    Hayashi H; Takiguchi Y; Minami H; Akiyoshi K; Segawa Y; Ueda H; Iwamoto Y; Kondoh C; Matsumoto K; Takahashi S; Yasui H; Sawa T; Onozawa Y; Chiba Y; Togashi Y; Fujita Y; Sakai K; Tomida S; Nishio K; Nakagawa K
    JAMA Oncol; 2020 Dec; 6(12):1931-1938. PubMed ID: 33057591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression profiling identifies responsive patients with cancer of unknown primary treated with carboplatin, paclitaxel, and everolimus: NCCTG N0871 (alliance).
    Yoon HH; Foster NR; Meyers JP; Steen PD; Visscher DW; Pillai R; Prow DM; Reynolds CM; Marchello BT; Mowat RB; Mattar BI; Erlichman C; Goetz MP
    Ann Oncol; 2016 Feb; 27(2):339-44. PubMed ID: 26578722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
    Hainsworth JD; Greco FA
    Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
    Pentheroudakis G; Greco FA; Pavlidis N
    Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overview of various techniques/platforms with critical evaluation of each.
    Agwa E; Ma PC
    Curr Treat Options Oncol; 2013 Dec; 14(4):623-33. PubMed ID: 24243164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
    Greco FA
    Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
    Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
    JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-specific Chemotherapy Based on Predicted Primary Site by Pathological Profile for Carcinoma of Unknown Primary Site.
    Hasegawa H; Ando M; Yatabe Y; Mitani S; Honda K; Masuishi T; Narita Y; Taniguchi H; Kadowaki S; Ura T; Muro K
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):667-673. PubMed ID: 30196846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal Cell Carcinoma Presenting as Carcinoma of Unknown Primary Site: Recognition of a Treatable Patient Subset.
    Greco FA; Hainsworth JD
    Clin Genitourin Cancer; 2018 Aug; 16(4):e893-e898. PubMed ID: 29610002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    Mol Diagn Ther; 2015 Apr; 19(2):91-7. PubMed ID: 25758902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology.
    Greco FA; Lennington WJ; Spigel DR; Hainsworth JD
    J Natl Cancer Inst; 2013 Jun; 105(11):782-90. PubMed ID: 23641043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
    Hainsworth JD; Spigel DR; Burris HA; Shipley D; Farley C; Macias-Perez IM; Barton J; Greco FA
    Cancer; 2010 May; 116(10):2448-54. PubMed ID: 20209610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Capecitabine and oxaliplatin as second-line treatment in patients with carcinoma of unknown primary site.
    Møller AK; Pedersen KD; Abildgaard J; Petersen BL; Daugaard G
    Acta Oncol; 2010 May; 49(4):431-5. PubMed ID: 20235750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New strategies for the treatment of carcinoma of unknown primary].
    Li LX; Zhang D; Ma F
    Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):44-49. PubMed ID: 36709119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction.
    Greco FA; Spigel DR; Yardley DA; Erlander MG; Ma XJ; Hainsworth JD
    Oncologist; 2010; 15(5):500-6. PubMed ID: 20427384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer of unknown primary site: evolving understanding and management of patients.
    Greco FA
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):518-24. PubMed ID: 23073050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.